Saving half the women diagnosed with ovarian cancer.
AOA has developed the first liquid biopsy test that accurately enables the early diagnosis of ovarian cancer through the analysis of tumor marker gangliosides. With approx. 80% of ovarian cancer cases only detected at stages III and IV, AOA provides the potential to reduce the number of deaths from this diagnosis by half, significantly reduce the costs of treatment and recurrence, and save countless women’s lives.
Read More